Thursday, July 9, 2026

Patent intelligence · US

US 11591336

Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors

granted A61KA61K45/06A61PA61P19/06
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 17
Applicant portfolio 12
Patent details — US 11591336
Jurisdiction
US
Status
granted
Grant date
Feb 28, 2023
Expiration
Feb 23, 2043
Claims
54
CPC classes
A61K, A61K45/06, A61P, A61P19/06
View on Google Patents ↗

Quick answer

US 11591336 (Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
54
CPC classes
A61K, A61K45/06, A61P, A61P19/06, A61P3/00, A61P35/00

More from Relay Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12331056

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Expires Jun 12, 2045

    granted
  2. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. · Expires Jan 30, 2045

    granted
  3. US 12152034

    FGFR inhibitors and methods of making and using the same

    Relay Therapeutics, Inc. · Expires Nov 21, 2044

    granted
  4. US 12138263

    Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Expires Nov 7, 2044

    granted
  5. US 12084447

    SHP2 phosphatase inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Expires Sep 5, 2044

    granted
  6. US 11890281

    SHP2 phosphatase inhibitors and methods of making and using the same

    Relay Therapeutics, Inc. · Expires Feb 1, 2044

    granted
  7. US 11780845

    FGFR inhibitors and methods of use thereof

    Relay Therapeutics, Inc. · Expires Oct 5, 2043

    granted
  8. US 11701354

    Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

    Relay Therapeutics, Inc. · Expires Jul 13, 2043

    granted

Frequently asked questions

What is US patent 11591336?

US 11591336 (Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors) is held by Relay Therapeutics, Inc.. Status: granted. Granted Feb 28, 2023. Expires Feb 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11591336?

Relay Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 11591336 expire?

Our index shows an expiration date of Feb 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.